June 18th 2024
Jakub Svoboda, MD, discusses the investigation of huCART19-IL18 in patients with relapsed/refractory lymphomas that have progressed.
June 10th 2024
Jakub Svoboda, MD, discusses outcomes with armored huCART19-IL18 in patients with previously treated relapsed/refractory lymphomas that have progressed.
June 19th 2023
Jakub Svoboda, MD, discusses the implications of the phase 3 SWOG 1826 trial of nivolumab plus doxorubicin, vinblastine, and dacarbazine in patients with advanced classical Hodgkin lymphoma.